ArticleBMC infectious diseases2026
Second-line antiretroviral therapy success rates and predictors among people living with HIV in Rwanda, 2019-2023.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite advances in HIV treatment, managing people living with HIV (PLHIV) on second-line antiretroviral therapy (ART) remains challenging. Globally, second-line ART achieves an average viral suppression rate (VLS) of 81.2%. In Rwanda, evidence is limited; the most recent national study in 2016 reported a 17% failure rate. This study assessed current VLS proportions and predictors of second-line ART success in Rwanda.
methodsA retrospective cohort study was conducted at 277 health facilities across Rwanda, including PLHIV who initiated second-line ART between January 2019 and December 2023. The primary outcome was VLS, defined as a viral load of ≤ 1000 copies/mL at the most recent measurement recorded at least six months after second-line initiation. Data were abstracted from patient files using a standardized tool, and multivariate logistic regression identified independent predictors of VLS.
resultsAnalysis included 726 individuals; overall VLS was 88.8% (645/726). Most participants were female (63.9%), aged 35-49 years (38.7%), on protease inhibitor-based regimens (78.7%), and on ART for 10 years or more (80.9%). Participants aged 15-24 years had lower odds of VLS compared with the 35-49 year reference group (aOR = 0.34; 95% CI: 0.13-0.92), and students had lower odds than participants (aOR = 0.18; 95% CI: 0.06-0.51). Residence in Kigali City (aOR = 2.47; 95% CI: 1.07-6.26), Northern (aOR = 3.57; 95% CI: 1.37-10.95), and Southern Province (aOR = 3.84; 95% CI: 1.58-10.53) was independently associated with higher odds of VLS compared with Eastern Province. PLHIV with poor or moderate ART adherence had 0.25 times the odds of VLS (aOR = 0.25; 95% CI: 0.14-0.44); alcohol or illicit drug use (aOR = 0.44; 95% CI: 0.22-0.94) and NCD comorbidity (aOR = 0.22; 95% CI: 0.06-0.80) were also independently associated with lower VLS.
conclusionRwanda's second-line VLS of 88.8% exceeds the global average and improves on the 2016 estimate but remains below the UNAIDS 95% target. Targeted interventions addressing adherence, substance use, and regional disparities, and integrated NCD services are needed. Tailored youth-friendly care, peer support, and integrated mental health services should be prioritized to improve outcomes among younger populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.